-
1
-
-
69249184799
-
-
Australian Bureau of Statistics (2007a) 2006 Census Table. http://www.abs.gov.au/
-
(2007)
2006 Census Table
-
-
-
2
-
-
68149100184
-
-
Australian Bureau of Statistics (2007b) 2006 QuickStats Australia. http://www.censusdata.abs.gov.au/ABSNavigation/prenav/ViewData?subaction= -1&producttype=QuickStats&areacode=0&action=401&collection= Census&textversion=false&breadcrumb=PL&period=2006&javascript= true&navmapdisplayed=true&
-
Australian Bureau of Statistics (2007b) 2006 QuickStats Australia. http://www.censusdata.abs.gov.au/ABSNavigation/prenav/ViewData?subaction= -1&producttype=QuickStats&areacode=0&action=401&collection= Census&textversion=false&breadcrumb=PL&period=2006&javascript= true&navmapdisplayed=true&
-
-
-
-
3
-
-
68149173077
-
-
Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. 9-8-2006
-
Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. 9-8-2006
-
-
-
-
4
-
-
0035873327
-
The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial
-
Cohen L, de MC, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial. Cancer 91: 1949-1955
-
(2001)
Cancer
, vol.91
, pp. 1949-1955
-
-
Cohen, L.D.M.1
Amato, R.J.2
-
5
-
-
3242660084
-
Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: A review
-
Crott R (2004) Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 22: 569-580
-
(2004)
Pharmacoeconomics
, vol.22
, pp. 569-580
-
-
Crott, R.1
-
6
-
-
3843097006
-
Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec
-
Crott R, Ali F, Burdette-Radoux S (2004) Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 7: 423-432
-
(2004)
Value Health
, vol.7
, pp. 423-432
-
-
Crott, R.1
Ali, F.2
Burdette-Radoux, S.3
-
7
-
-
38349131636
-
Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of 3 alternative theories
-
Dale W, Basu A, Elstein A, Meltzer D (2002) Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making 28: 102-112
-
(2002)
Med Decis Making
, vol.28
, pp. 102-112
-
-
Dale, W.1
Basu, A.2
Elstein, A.3
Meltzer, D.4
-
8
-
-
33344456866
-
Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial
-
Dixon S, Walters SJ, Turner L, Hancock BW (2006) Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 94: 492-498
-
(2006)
Br J Cancer
, vol.94
, pp. 492-498
-
-
Dixon, S.1
Walters, S.J.2
Turner, L.3
Hancock, B.W.4
-
9
-
-
36748999428
-
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
-
Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6681-6688
-
-
Downey, S.G.1
Klapper, J.A.2
Smith, F.O.3
Yang, J.C.4
Sherry, R.M.5
Royal, R.E.6
Kammula, U.S.7
Hughes, M.S.8
Allen, T.E.9
Levy, C.L.10
Yellin, M.11
Nichol, G.12
White, D.E.13
Steinberg, S.M.14
Rosenberg, S.A.15
-
10
-
-
68149148295
-
-
England and Wales Census, Data Table
-
England and Wales Census 2007 England and Wales Census, 2001 Data Table. http://www.statistics.gov.uk/census2001/table-list-cas.asp
-
(2007)
England and Wales Census, 2001
-
-
-
11
-
-
33750981248
-
Deriving utility scores for co-morbid conditions: A test of the multiplicative model for combining individual condition scores
-
Flanagan W, McIntosh CN, Le PC, Berthelot JM (2006) Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr 4: 13
-
(2006)
Popul Health Metr
, vol.4
, pp. 13
-
-
Flanagan, W.1
McIntosh2
CN, L.P.3
Berthelot, J.M.4
-
12
-
-
50949093888
-
Utilities should not be multiplied: Evidence from the preference-based scores in the United States
-
Fu AZ, Kattan MW (2008) Utilities should not be multiplied: evidence from the preference-based scores in the United States. Medical Care 46: 984-990
-
(2008)
Medical Care
, vol.46
, pp. 984-990
-
-
Fu, A.Z.1
Kattan, M.W.2
-
13
-
-
0346096833
-
Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine
-
Kiebert GM, Jonas DL, Middleton MR (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21: 821-829
-
(2003)
Cancer Invest
, vol.21
, pp. 821-829
-
-
Kiebert, G.M.1
Jonas, D.L.2
Middleton, M.R.3
-
14
-
-
0036499079
-
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data
-
Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease Jr RF, Weeks JC (2002) Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20: 1311-1318
-
(2002)
J Clin Oncol
, vol.20
, pp. 1311-1318
-
-
Kilbridge, K.L.1
Cole, B.F.2
Kirkwood, J.M.3
Haluska, F.G.4
Atkins, M.A.5
Ruckdeschel, J.C.6
Sock, D.E.7
Nease Jr, R.F.8
Weeks, J.C.9
-
15
-
-
0035253368
-
Patient preferences for adjuvant interferon alfa-2b treatment
-
Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, Sock DE, Kirkwood JM, Nease RF (2001) Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19: 812-823
-
(2001)
J Clin Oncol
, vol.19
, pp. 812-823
-
-
Kilbridge, K.L.1
Weeks, J.C.2
Sober, A.J.3
Haluska, F.G.4
Slingluff, C.L.5
Atkins, M.B.6
Sock, D.E.7
Kirkwood, J.M.8
Nease, R.F.9
-
16
-
-
39149104690
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
-
Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-534
-
(2008)
J Clin Oncol
, vol.26
, pp. 527-534
-
-
Korn, E.L.1
Liu, P.Y.2
Lee, S.J.3
Chapman, J.A.4
Niedzwiecki, D.5
Suman, V.J.6
Moon, J.7
Sondak, V.K.8
Atkins, M.B.9
Eisenhauer, E.A.10
Parulekar, W.11
Markovic, S.N.12
Saxman, S.13
Kirkwood, J.M.14
-
17
-
-
4544286541
-
-
National Institute for Clinical Excellence NICE
-
National Institute for Clinical Excellence (NICE) (2004) Guide to the Methods of Technology Appraisal. p 20.
-
(2004)
Guide to the Methods of Technology Appraisal
, pp. 20
-
-
-
18
-
-
36849035139
-
-
NICE: London O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627
-
NICE: London O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627
-
-
-
-
21
-
-
22244440228
-
A national catalog of preference-based scores for chronic conditions in the United States
-
Sullivan PW, Lawrence WF, Ghushchyan V (2005) A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43: 736-749
-
(2005)
Med Care
, vol.43
, pp. 736-749
-
-
Sullivan, P.W.1
Lawrence, W.F.2
Ghushchyan, V.3
-
22
-
-
0022633115
-
Measurement of health state utilities for economic appraisal
-
Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5: 1-30
-
(1986)
J Health Econ
, vol.5
, pp. 1-30
-
-
Torrance, G.W.1
-
23
-
-
0003486933
-
-
World Health Organization , WHO publication no. 48: Geneva, Switzerland
-
World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48: Geneva, Switzerland
-
(1979)
Handbook for Reporting Results of Cancer Treatment
-
-
|